Catheter Precision Q3 Revenue Rises 135% to $226,000

Reuters

Nov 14, 2025

Catheter Precision Q3 Revenue Rises 135% to $226,000

Catheter Precision Inc. reported total revenue of $226,000 for the third quarter of 2025, an increase of 135% compared to $96,000 in the same period of 2024. Revenue for the first nine months of 2025 was $581,000, up 114% from $271,000 in the first nine months of 2024. The GAAP net loss for the third quarter of 2025 was $2.3 million, a 45% reduction from $4.1 million in the third quarter of 2024. For the first nine months of 2025, the GAAP net loss was $11.4 million compared to $11.0 million for the same period in 2024. Business developments for the period included increased sales activities for the LockeT device outside the United States, following CE Mark approval, with new interest in several European countries and South Africa. Five accounts in South Africa placed reorders in October. Sales of the VIVO product line also expanded internationally, with the first purchase order from France in October. The company completed two VIVO clinical studies in 2025 and continued to prioritize clinical studies and publications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Catheter Precision Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9575527-en) on November 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2583755514"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583755514\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583755514?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 05:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583755514","market":"fut","top_or_hot":-1,"title":"Catheter Precision Q3 Revenue Rises 135% to $226,000","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Catheter Precision Q3 Revenue Rises 135% to $226,000\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VTAK\">Catheter Precision Inc.</a> reported total revenue of $226,000 for the third quarter of 2025, an increase of 135% compared to $96,000 in the same period of 2024. Revenue for the first nine months of 2025 was $581,000, up 114% from $271,000 in the first nine months of 2024. The GAAP net loss for the third quarter of 2025 was $2.3 million, a 45% reduction from $4.1 million in the third quarter of 2024. For the first nine months of 2025, the GAAP net loss was $11.4 million compared to $11.0 million for the same period in 2024. Business developments for the period included increased sales activities for the LockeT device outside the United States, following CE Mark approval, with new interest in several European countries and South Africa. Five accounts in South Africa placed reorders in October. Sales of the VIVO product line also expanded internationally, with the first purchase order from France in October. The company completed two VIVO clinical studies in 2025 and continued to prioritize clinical studies and publications.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Catheter Precision Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9575527-en) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Catheter Precision Q3 Revenue Rises 135% to $226,000</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCatheter Precision Q3 Revenue Rises 135% to $226,000\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-14 05:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Catheter Precision Q3 Revenue Rises 135% to $226,000\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VTAK\">Catheter Precision Inc.</a> reported total revenue of $226,000 for the third quarter of 2025, an increase of 135% compared to $96,000 in the same period of 2024. Revenue for the first nine months of 2025 was $581,000, up 114% from $271,000 in the first nine months of 2024. The GAAP net loss for the third quarter of 2025 was $2.3 million, a 45% reduction from $4.1 million in the third quarter of 2024. For the first nine months of 2025, the GAAP net loss was $11.4 million compared to $11.0 million for the same period in 2024. Business developments for the period included increased sales activities for the LockeT device outside the United States, following CE Mark approval, with new interest in several European countries and South Africa. Five accounts in South Africa placed reorders in October. Sales of the VIVO product line also expanded internationally, with the first purchase order from France in October. The company completed two VIVO clinical studies in 2025 and continued to prioritize clinical studies and publications.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Catheter Precision Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9575527-en) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"纳斯达克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL3qvgD0:1","article_id":"2583755514","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583755514","pubTimestamp":1763068527,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Catheter Precision Inc. reported total revenue of $226,000 for the third quarter of 2025, an increase of 135% compared to $96,000 in the same period of 2024. Revenue for the first nine months of 2025 was $581,000, up 114% from $271,000 in the first nine months of 2024. The GAAP net loss for the third quarter of 2025 was $2.3 million, a 45% reduction from $4.1 million in the third quarter of 2024. For the first nine months of 2025, the GAAP net loss was $11.4 million compared to $11.0 million for the same period in 2024. Business developments for the period included increased sales activities for the LockeT device outside the United States, following CE Mark approval, with new interest in several European countries and South Africa. Five accounts in South Africa placed reorders in October. Sales of the VIVO product line also expanded internationally, with the first purchase order from France in October. The company completed two VIVO clinical studies in 2025 and continued to prioritize ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","VTAK":"Catheter Precision Inc.","BK4588":"碎股","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4585":"ETF&股票定投概念","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4082":"医疗保健设备","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"Catheter Precision第三季度收入增长135%至226,000美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTAK":0.9,"NDAQ":0.9},"content_text":"Catheter Precision Q3 Revenue Rises 135% to $226,000\n    \n\nCatheter Precision Inc. reported total revenue of $226,000 for the third quarter of 2025, an increase of 135% compared to $96,000 in the same period of 2024. Revenue for the first nine months of 2025 was $581,000, up 114% from $271,000 in the first nine months of 2024. The GAAP net loss for the third quarter of 2025 was $2.3 million, a 45% reduction from $4.1 million in the third quarter of 2024. For the first nine months of 2025, the GAAP net loss was $11.4 million compared to $11.0 million for the same period in 2024. Business developments for the period included increased sales activities for the LockeT device outside the United States, following CE Mark approval, with new interest in several European countries and South Africa. Five accounts in South Africa placed reorders in October. Sales of the VIVO product line also expanded internationally, with the first purchase order from France in October. The company completed two VIVO clinical studies in 2025 and continued to prioritize clinical studies and publications.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Catheter Precision Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9575527-en) on November 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}